SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Mimedx Group, Inc. – ‘10-K’ for 12/31/12 – ‘R40’

On:  Friday, 3/15/13, at 5:14pm ET   ·   For:  12/31/12   ·   Accession #:  1140361-13-12765   ·   File #:  0-52491

Previous ‘10-K’:  ‘10-K/A’ on 6/21/12 for 12/31/11   ·   Next:  ‘10-K’ on 3/4/14 for 12/31/13   ·   Latest:  ‘10-K’ on 2/28/24 for 12/31/23

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/15/13  Mimedx Group, Inc.                10-K       12/31/12   70:10M                                    Broadridge Fin’l So… Inc

Annual Report   —   Form 10-K   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Mimedx Group Inc 10-K 12-31-2012                    HTML   1.04M 
 2: EX-10.54    Material Contract                                   HTML     39K 
 3: EX-10.55    Material Contract                                   HTML     27K 
 4: EX-10.56    Material Contract                                   HTML     96K 
 5: EX-23.1     Consent of Experts or Counsel                       HTML     19K 
 6: EX-31.1     Certification -- §302 - SOA'02                      HTML     27K 
 7: EX-31.2     Certification -- §302 - SOA'02                      HTML     27K 
 8: EX-32.1     Certification -- §906 - SOA'02                      HTML     21K 
 9: EX-32.2     Certification -- §906 - SOA'02                      HTML     21K 
47: R1          Document and Entity Information                     HTML     48K 
37: R2          Consolidated Balance Sheets                         HTML    126K 
45: R3          Consolidated Balance Sheets (Parenthetical)         HTML     56K 
49: R4          Consolidated Statements of Operations               HTML     70K 
64: R5          Consolidated Statements of Stockholders' Equity     HTML    130K 
39: R6          Consolidated Statements of Stockholders' Equity     HTML     22K 
                (Parenthetical)                                                  
44: R7          Consolidated Statements of Cash Flows               HTML    150K 
34: R8          Consolidated Statements of Cash Flows               HTML     76K 
                (Parenthetical)                                                  
26: R9          Nature of Business                                  HTML     24K 
66: R10         Significant Accounting Policies                     HTML    124K 
51: R11         Liquidity and Management's Plans                    HTML     22K 
50: R12         Acquisition of Surgical Biologics, LLC              HTML     85K 
55: R13         Inventories                                         HTML     33K 
56: R14         Property and Equipment                              HTML     36K 
54: R15         Intangible Assets and Royalty Agreement             HTML     96K 
57: R16         Accrued Expenses                                    HTML     30K 
46: R17         Long-Term Debt                                      HTML     54K 
48: R18         Common Stock Placements                             HTML     36K 
53: R19         Equity                                              HTML    185K 
70: R20         Income Taxes                                        HTML     58K 
60: R21         Related Party Transactions                          HTML     38K 
41: R22         401k Plan                                           HTML     30K 
52: R23         Commitments                                         HTML     30K 
43: R24         Subsequent Events                                   HTML     24K 
20: R25         Significant Accounting Policies (Policies)          HTML    222K 
61: R26         Significant Accounting Policies (Tables)            HTML     65K 
67: R27         Acquisition of Surgical Biologics, LLC (Tables)     HTML     72K 
30: R28         Inventories (Tables)                                HTML     30K 
29: R29         Property and Equipment (Tables)                     HTML     33K 
32: R30         Intangible Assets and Royalty Agreement (Tables)    HTML     96K 
33: R31         Accrued Expenses (Tables)                           HTML     27K 
35: R32         Long-Term Debt (Tables)                             HTML     47K 
19: R33         Equity (Tables)                                     HTML    182K 
58: R34         Income Taxes (Tables)                               HTML     50K 
40: R35         Related Party Transactions (Tables)                 HTML     33K 
42: R36         Commitments (Tables)                                HTML     25K 
23: R37         Nature of Business (Details)                        HTML     21K 
69: R38         Significant Accounting Policies (Details)           HTML    157K 
16: R39         Liquidity and Management's Plans (Details)          HTML     31K 
36: R40         Acquisition of Surgical Biologics, LLC (Details)    HTML    177K 
63: R41         Inventories (Details)                               HTML     38K 
22: R42         Property and Equipment (Details)                    HTML     34K 
28: R43         Intangible Assets and Royalty Agreement (Details)   HTML    122K 
31: R44         Accrued Expenses (Details)                          HTML     31K 
38: R45         Long-Term Debt (Details)                            HTML    116K 
18: R46         Common Stock Placements (Details)                   HTML     70K 
25: R47         Equity (Details)                                    HTML    285K 
17: R48         Income Taxes (Details)                              HTML     95K 
62: R49         Related Party Transactions (Details)                HTML     31K 
21: R50         401k Plan (Details)                                 HTML     32K 
59: R51         Commitments (Details)                               HTML     28K 
24: R52         Subsequent Events (Details)                         HTML     37K 
68: XML         IDEA XML File -- Filing Summary                      XML     94K 
27: EXCEL       IDEA Workbook of Financial Reports (.xls)            XLS   1.52M 
10: EX-101.INS  XBRL Instance -- mdxg-20121231                       XML   2.21M 
12: EX-101.CAL  XBRL Calculations -- mdxg-20121231_cal               XML    193K 
13: EX-101.DEF  XBRL Definitions -- mdxg-20121231_def                XML    640K 
14: EX-101.LAB  XBRL Labels -- mdxg-20121231_lab                     XML   2.22M 
15: EX-101.PRE  XBRL Presentations -- mdxg-20121231_pre              XML   1.17M 
11: EX-101.SCH  XBRL Schema -- mdxg-20121231                         XSD    203K 
65: ZIP         XBRL Zipped Folder -- 0001140361-13-012765-xbrl      Zip    225K 


‘R40’   —   Acquisition of Surgical Biologics, LLC (Details)


This is an IDEA Financial Report.  [ Alternative Formats ]



 
v2.4.0.6
Acquisition of Surgical Biologics, LLC (Details) (USD $)
0 Months Ended 1 Months Ended 12 Months Ended
Business Acquisition [Line Items]          
Cash Paid $ 500,000        
Convertible secured promissory note 1,250,000        
Convertible Promissory Notes, interest rate (in hundredths) 4.00%        
Common Stock valued 7,087,500 893,267      
Common Stock issued (in shares) 5,250,000   2,632,576    
Value of shares issued (in dollars per share) $ 1.35        
Common stock held in escrow (in shares) 525,000        
Convertible Promissory Note, conversion price (in dollars per share)       $ 1.00  
Convertible promissory note, stock price trigger (in dollars per share)       $ 1.75  
Number of consecutive trading days       20 days  
Maturity period of convertible promissory notes       18 months  
Repayments of Convertible Debt   177,000   427,126 0
Accrued Earn Out [Roll Forward]          
Beginning balance at beginning period       7,410,503 0
Valuation at acquisition date 7,404,700       0
Remeasurement adjustments       1,567,050 5,803
Common stock issued for earn-out liability       (3,185,223) 0
Ending balance at ending period       5,792,330 7,410,503
Actual purchase price allocated [Abstract]          
Value of 5,250,000 shares issued at $1.35 per share 7,087,500        
Cash paid at closing 350,000        
Cash retained for working capital 150,000        
Assumed Debt 182,777        
Convertible Secured Promissory Note 1,250,000        
Fair value of earn-out 7,404,700        
Total fair value of purchase price 16,424,977        
Tangible assets [Abstract]          
Debt-free working capital 671,880        
Other assets, net 385        
Property, plant and equipment 72,866        
Tangible assets purchased 745,131        
Acquired Indefinite-lived Intangible Assets [Line Items]          
Total acquired intangible assets 12,497,000        
Goodwill 3,182,846        
Total Assets Purchased 16,424,977        
Working capital [Abstract]          
Cash 33,583        
Prepaid Expenses 2,738        
Accounts Receivable 181,087        
License Receivable 340,000        
Inventory 347,106        
Accounts payable and accrued expenses (196,101)        
Deferred rent and customer deposits (36,533)        
Debt-free working capital 671,880        
Current portion of debt (62,590)        
Long-term debt (21,187)        
Line of credit (99,000)        
Net working capital 489,103        
Deposits 16,582        
Deferred rent (non-current) (16,197)        
Deposits net of deferred rent (non-current) 385        
Trade names and trademarks [Member]
         
Acquired Indefinite-lived Intangible Assets [Line Items]          
Acquired intangible asset 1,008,000        
Estimated useful life (in years)       indefinite  
In-process research and development - liquid [Member]
         
Acquired Indefinite-lived Intangible Assets [Line Items]          
Acquired intangible asset 2,160,000        
Estimated useful life (in years)       indefinite [1]  
In-process research and development - other [Member]
         
Acquired Indefinite-lived Intangible Assets [Line Items]          
Acquired intangible asset 25,000        
Estimated useful life (in years)       indefinite  
Customer Relationships [Member]
         
Acquired Finite-Lived Intangible Assets [Line Items]          
Acquired intangible assets 3,520,000        
Estimated useful life (in years)       14 years  
Supplier Relationships [Member]
         
Acquired Finite-Lived Intangible Assets [Line Items]          
Acquired intangible assets 241,000        
Estimated useful life (in years)       14 years  
Patents and Know-How [Member]
         
Acquired Finite-Lived Intangible Assets [Line Items]          
Acquired intangible assets 5,530,000        
Estimated useful life (in years)       14 years  
Licenses and Permits [Member]
         
Acquired Finite-Lived Intangible Assets [Line Items]          
Acquired intangible assets $ 13,000        
Estimated useful life (in years)       3 years  
[1] AmnioFix injectable was launched in 2012 with amortization recorded over its expected useful life.

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-K’ Filing    Date    Other Filings
Filed on:3/15/13
For Period end:12/31/12
7/31/12
4/30/12
12/31/1110-K,  10-K/A
1/5/114,  8-K,  8-K/A
9/15/094
 List all Filings 
Top
Filing Submission 0001140361-13-012765   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Sat., Apr. 27, 6:31:25.2pm ET